论文部分内容阅读
目的探讨T2DM合并结直肠癌患者的临床病理特征和二甲双胍对肿瘤分化程度及转移的影响。方法检测研究对象FPG、血白蛋白(Alb)、BUN、血肌酐(Scr)、血尿酸(SUA)、TG、TC、HDLC、LDL-C和极低密度脂蛋白胆固醇(VLDL-C)水平,观察结直肠癌病理分级、结直肠癌淋巴结及远处转移情况。结果按照患者诊断结直肠癌时是否服用二甲双胍进行分组后发现,二甲双胍组低分化腺癌比例及远处转移率均低于无二甲双胍组(P<0.05)。结论 T2DM合并结直肠癌患者口服二甲双胍降糖,其肿瘤预后较好。
Objective To investigate the clinicopathological features of patients with T2DM complicated with colorectal cancer and the effect of metformin on tumor differentiation and metastasis. Methods The levels of FPG, Alb, BUN, Scr, SUA, TG, TC, HDLC, LDL-C and VLDL- To observe the pathological grade of colorectal cancer, colorectal cancer lymph nodes and distant metastasis. Results According to whether patients were treated with metformin for diagnosis of colorectal cancer, the rate of poorly differentiated adenocarcinoma and distant metastasis in metformin group was lower than that in the group without metformin (P <0.05). Conclusions Metformin in T2DM patients with colorectal cancer is hypoglycemic, and its prognosis is good.